Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 602 Shares

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 602 shares of the stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $139.29, for a total transaction of $83,852.58. Following the transaction, the chief financial officer owned 71,414 shares in the company, valued at approximately $9,947,256.06. The trade was a 0.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, July 22nd, Michael Burkes Brophy sold 920 shares of Natera stock. The stock was sold at an average price of $139.58, for a total transaction of $128,413.60.
• On Thursday, July 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The stock was sold at an average price of $139.50, for a total transaction of $105,322.50.
• On Wednesday, July 23rd, Michael Burkes Brophy sold 495 shares of Natera stock. The stock was sold at an average price of $141.28, for a total transaction of $69,933.60.
• On Monday, April 28th, Michael Burkes Brophy sold 2,018 shares of Natera stock. The stock was sold at an average price of $152.18, for a total transaction of $307,099.24.

Natera Stock Down 1.5%

NASDAQ:NTRA traded down $2.17 during trading hours on Friday, reaching $138.90. The company had a trading volume of 1,202,980 shares, compared to its average volume of 1,211,392. The firm has a market cap of $18.97 billion, a price-to-earnings ratio of -94.49 and a beta of 1.73. The business's 50-day simple moving average is $159.07 and its two-hundred day simple moving average is $157.34. Natera, Inc. has a twelve month low of $92.14 and a twelve month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The business's quarterly revenue was up 36.5% on a year-over-year basis. During the same period last year, the company posted ($0.56) earnings per share. As a group, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on NTRA. Barclays raised their target price on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Piper Sandler raised their target price on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Thursday, May 15th. Finally, UBS Group raised their price target on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus target price of $184.63.

Institutional Investors Weigh In On Natera

Large investors have recently bought and sold shares of the stock. HighPoint Advisor Group LLC grew its holdings in Natera by 30.8% in the first quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock worth $308,000 after purchasing an additional 468 shares during the period. Amalgamated Bank grew its holdings in shares of Natera by 9.8% during the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock valued at $1,173,000 after buying an additional 740 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Natera by 32.3% during the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock valued at $120,000 after buying an additional 207 shares during the last quarter. Teza Capital Management LLC acquired a new position in shares of Natera during the fourth quarter valued at about $221,000. Finally, Asset Management One Co. Ltd. acquired a new position in shares of Natera during the first quarter valued at about $6,753,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.